VistaGen Therapeutics Inc (VTGN)

[notoriousinvestor]

Congratulations folks, regardless of all types of negativity on the boards Shawn Singh and his distinguished board of directors decided to stay with the Autillion group and declined to raise money from their own source. Which they have already raised 55 million dollars from this source.

What this tells me is that they're extremely satisfied working with Bergamo and they went ahead to release a press release, 8k filing and accepted nominal payment and to show their confidence, exercised their own warrants.

Shawn Singh needed the support of his board of directors to approve this deal, thus proving the 2009 group very wrong by doing this.

Now these people have already sold 2 prior companies for millions of millions dollars.FYI: Mr. Shawn Singh has also been an investment banker in the past.

If Warren Buffett would show interest in this deal, this 2009 group would still find a way to bash it.

This is for the new investors and supporters, please ask me and don't listen to the negative 2009 group


Board of Directors

Jon S. Saxe,
Chairman

Brian J. Underdown, Ph.D.,
Director

H. Ralph Snodgrass, Ph.D.,
Founder, President and Chief Scientific Officer

Shawn K. Singh, J.D.
Chief Executive Officer

Management Team

Shawn K. Singh, J.D.
Chief Executive Officer, Director

H. Ralph Snodgrass, Ph.D.
Founder, President and Chief Scientific Officer, Director

Jerrold D. Dotson, CPA
Acting Chief Financial Officer

A. Franklin Rice, MBA
VP of Corporate Development, Secretary

Scientific Advisory Board

Gordon Keller, Ph.D.
Chairman, Director, McEwen Centre for Regenerative Medicine, University Health Network

Peter Backx, D.V.M., Ph.D.
Professor, University of Toronto, Departments of Physiology and Medicine

George Clay, Ph.D.
Chief Operating Officer (retired), Kyowa Pharmaceuticals

Arthur Fetter, D.V.M., Ph.D.
Sr. Vice President (retired), Worldwide Drug Safety, Rhone-Poulenc Rorer

Jack Gauldie, Ph.D.
Director, Centre for Gene Therapeutics, McMaster University

John Lowe, Ph.D.
Senior Research Fellow (retired), Medicinal Chemistry and Drug Discovery, Pfizer Global R&D

James E. Sanders, D.V.M., Ph.D.
Senior Director and Preclinical Development Leader (retired), Johnson & Johnson

Ron Wester, Ph.D. Vice President (retired)
Medicinal Chemistry and Drug Discovery, Pfizer Global R&D